3/1/2021 2:32:40 PM
Aikido Pharma is developing a drug portfolio to
Aikido Pharma is developing a drug portfolio to treat acute myeloid leukemia (AML) cancer along with three other main cancer types. Our AML drug, developed at Wake Forest University, is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. Get in touch with Aikido Pharma today by calling 212-745-1373.
-
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
2/28/2021 4:30:00 AM
2/28/2021 2:30:00 AM
2/28/2021 1:30:00 AM
2/28/2021 12:30:00 AM
2/27/2021 9:30:00 PM
2/27/2021 4:30:00 AM
2/27/2021 2:30:00 AM
2/27/2021 1:30:00 AM
2/27/2021 12:30:00 AM
2/26/2021 10:30:00 PM
2/26/2021 9:30:00 PM
2/26/2021 4:30:00 AM
2/26/2021 1:30:00 AM
2/26/2021 1:00:00 AM
Report This Post
Please complete the following requested information to flag this post and report abuse, or offensive content. Your report will be reviewed within 24 hours. We will take appropriate action as described in Findit terms of use.
